AI & Digital Health: Technology and Beyond
The healthcare sector is growing and so is the data that is associated with this industry. In this dynamic scenario, the effectiveness with which the data is utilized becomes critical.
Since last year, CFIUS has expanded its scope to parts of health and life sciences, and data that may be collected or held by life sciences companies, including genomic or health data, is likely to be included in such regulations.
Many biotech companies that historically haven’t been subject to such controls will need to consider these restrictions, including when taking investments, collaborating with non-US persons on technology development, and exporting products.
At China Focus@BIO Philadelphia, we have invited professionals in big data and AI based technology, pioneers in cross-border investment, experts in regulatory, marketing, and strategy to share their experiences and insights in this rapid-developing field.
Joining them are leaders in digital innovation from Sanofi, Johnson & Johnson, Novartis, and MedImmune, as well as prestigious consulting/research organizations such as PwC Health Research Institute, Frost & Sullivan, and Evolution Road LLC.